Acne Vulgaris
📧 Sign up to get email alerts when something new happens for Acne Vulgaris.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: P3 Study in Acne Comparing Once Daily SB204 and Vehicle [Phase 3]
Phase 3 trial in acne vulgaris comparing once-daily SB204 to vehicle has completed with results posted in 2023.
-
FDA approval · 2023-04-25FDA Approved: TAZAROTENE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved the original ANDA for tazarotene (TAZAROTENE) by Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2023-04-11FDA Approved: ADAPALENE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for adapalene from Actavis Pharma, Inc., under ANDA 201000. The action indicates regulatory appr…
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Subantimicrobial Doxycycline in Acne [Phase 4]
Phase 4 clinical trial evaluating subantimicrobial doxycycline for acne vulgaris in pediatric patients has completed with results posted.
-
FDA approval · 2023-03-30FDA Approved: SEYSARA — Supplemental Application (Almirall, LLC)
FDA approved a supplemental application for SEYSARA (sarecycline hydrochloride) from Almirall, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-29Clinical Trial Update: Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris [Phase 3]
Phase 3 study comparing IDP-120 Gel versus vehicle gel in acne vulgaris has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-03-29Clinical Trial Update: Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris [Phase 3]
A Phase 3 clinical trial comparing IDP-120 Gel vs IDP-120 Vehicle Gel in acne vulgaris has completed with results posted.
-
FDA approval · 2023-03-24FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc., under the approved ANDA, indica…
-
FDA approval · 2023-03-24FDA Approved: ABSORICA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approves a supplemental application for ABSORICA (isotretinoin) from Sun Pharmaceutical Industries, indicating a regulatory update r…
-
FDA label_change · 2023-03-24FDA Approved: ABSORICA LD — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ABSORICA LD (isotretinoin) to update its labeling. The sponsor is Sun Pharmaceutical Industries.
-
FDA approval · 2023-03-24FDA Approved: ISOTRETINOIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith Laboratories' supplemental application for isotretinoin.
-
FDA approval · 2023-03-24FDA Approved: ISOTRETINOIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for isotretinoin filed by Upsher-Smith Laboratories, LLC.
-
FDA approval · 2023-03-24FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for CLARAVIS (isotretinoin) by Teva Pharmaceuticals USA, Inc., under ANDA076135.
-
FDA approval · 2023-03-24FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Zenatane (isotretinoin) by BluePoint Laboratories (ANDA 202099).
-
FDA approval · 2023-03-24FDA Approved: ISOTRETINOIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for isotretinoin from Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2023-03-24FDA Approved: ISOTRETINOIN — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for isotretinoin by Actavis Pharma, Inc. for the generic product.
-
FDA approval · 2023-03-20FDA Approved: TAZAROTENE — Original Application (Solaris Pharma Corporation)
The FDA approved a generic version of tazarotene (topical retinoid) from Solaris Pharma Corporation through an Original Abbreviated New Drug…
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: The Efficacy and Safety of Topical Vitamin D and Supplementation In Acne Vulgaris The Study of VDR, IL-1β, IL-6, IL-10 and IL-17 Expression [Phase 4]
Phase 4 trial evaluating topical vitamin D and supplementation for acne vulgaris, examining VDR and inflammatory cytokine expression (IL-1β,…
-
FDA approval · 2023-03-02FDA Approved: ADAPALENE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved a supplemental application for adapalene from Alembic Pharmaceuticals, confirming approval of a generic adapalene product.
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne [Phase 4]
Phase 4 trial evaluating tazarotene 0.045% lotion for post-inflammatory hyperpigmentation and related skin changes in acne patients; study c…
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Serum TWEAK Levels in Acne Vulgaris [Phase 2]
Phase 2 clinical trial updating serum TWEAK levels in acne vulgaris has completed.
-
FDA approval · 2023-01-05FDA Approved: TRETINOIN — Original Application (NORTHSTAR RX LLC)
The FDA approved NorthStar RX LLC's original ANDA for tretinoin, enabling a generic topical retinoid product to reach the market.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris [Phase 4]
Phase 4 clinical trial comparing isotretinoin, silymarin, and combination therapy for acne vulgaris; status unknown.
-
CLINICAL_TRIALS trial_result · 2022-12-09Clinical Trial Update: A Treatment for Severe Inflammatory Acne Subjects [Phase 4]
Phase 4 trial update for a treatment targeting acne vulgaris completed with posted results.
-
FDA approval · 2022-12-07FDA Approved: DOXYCYCLINE — Original Application (Par Health USA, LLC)
FDA approved a generic doxycycline product under an original new drug application by Par Health USA, LLC (ANDA216690).